BR112018072993A2 - métodos para classificação de um paciente com um câncer sólido - Google Patents

métodos para classificação de um paciente com um câncer sólido

Info

Publication number
BR112018072993A2
BR112018072993A2 BR112018072993-0A BR112018072993A BR112018072993A2 BR 112018072993 A2 BR112018072993 A2 BR 112018072993A2 BR 112018072993 A BR112018072993 A BR 112018072993A BR 112018072993 A2 BR112018072993 A2 BR 112018072993A2
Authority
BR
Brazil
Prior art keywords
methods
solid cancer
classifying
cancer patient
responsiveness
Prior art date
Application number
BR112018072993-0A
Other languages
English (en)
Other versions
BR112018072993A8 (pt
Inventor
Galon Jérôme
Mlecnik Bernhard
Pages Franck
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Sorbonne Universite
Universite Paris Descartes
Université Paris Diderot - Paris 7
Assistance Publique - Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Sorbonne Universite, Universite Paris Descartes, Université Paris Diderot - Paris 7, Assistance Publique - Hôpitaux De Paris filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of BR112018072993A2 publication Critical patent/BR112018072993A2/pt
Publication of BR112018072993A8 publication Critical patent/BR112018072993A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção se refere a métodos para classificar pacientes que sofrem de um câncer sólido, particularmente a métodos para o prognóstico do tempo de sobrevivência de um paciente que sofre de um câncer sólido e / ou a métodos para avaliar a capacidade de resposta de um doente sofrendo de um câncer sólido ao tratamento antitumoral. o método se baseia na quantificação de múltiplos marcadores de resposta imune e na determinação de qual percentil da distribuição os valores correspondem quando comparados a uma distribuição de referência. calcular a média ou a mediana dos percentis determinados dos diferentes marcadores e comparar esse valor com um valor de referência dos percentis de média ou mediana, cujo resultado está correlacionado com a sobrevivência ou a capacidade de resposta.
BR112018072993A 2016-05-09 2017-05-09 Métodos para classificação de um paciente com um câncer sólido BR112018072993A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
EP16305536.1 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (2)

Publication Number Publication Date
BR112018072993A2 true BR112018072993A2 (pt) 2019-03-06
BR112018072993A8 BR112018072993A8 (pt) 2022-11-08

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072993A BR112018072993A8 (pt) 2016-05-09 2017-05-09 Métodos para classificação de um paciente com um câncer sólido

Country Status (14)

Country Link
US (1) US20190309369A1 (pt)
EP (1) EP3455631B1 (pt)
JP (3) JP7281903B2 (pt)
KR (1) KR102245021B1 (pt)
CN (2) CN115198018A (pt)
AU (1) AU2017261685B2 (pt)
BR (1) BR112018072993A8 (pt)
ES (1) ES2808004T3 (pt)
MX (1) MX2018013744A (pt)
PL (1) PL3455631T3 (pt)
RU (1) RU2745730C2 (pt)
SG (1) SG11201809317VA (pt)
WO (1) WO2017194556A1 (pt)
ZA (1) ZA201807020B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911541YA (en) 2017-06-13 2020-02-27 Bostongene Corp Systems and methods for identifying cancer treatments from normalized biomarker scores
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
DK3746790T3 (da) * 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
AU2020288603A1 (en) 2019-06-03 2021-12-16 Assistance Publique - Hôpitaux De Paris Methods for modulating a treatment regimen
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
EP4330676A1 (en) * 2021-04-27 2024-03-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
JP2024517986A (ja) * 2021-05-13 2024-04-23 セントリックスバイオ インコーポレイテッド 抗－ＣＤ３００ｃ抗体を利用した併用療法
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
WO2023233310A1 (en) * 2022-06-03 2023-12-07 Universita' Degli Studi Di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097B (zh) * 2023-10-25 2024-06-07 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2805165B1 (en) * 2012-01-20 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells
JP6449765B2 (ja) * 2012-06-14 2019-01-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 腫瘍組織における免疫細胞を定量するための方法及びその応用
PL2872646T3 (pl) * 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
PL2880180T3 (pl) * 2012-08-06 2019-04-30 Assist Publique Hopitaux De Paris Sposoby i zestawy do badań przesiewowych pacjentów z nowotworem
JP2016530505A (ja) * 2013-07-15 2016-09-29 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 固形癌を患う患者の生存期間の予後判定のための方法

Also Published As

Publication number Publication date
CN109690314B (zh) 2022-08-02
KR102245021B1 (ko) 2021-04-26
WO2017194556A1 (en) 2017-11-16
US20190309369A1 (en) 2019-10-10
ZA201807020B (en) 2020-05-27
AU2017261685A1 (en) 2018-11-15
JP2022027788A (ja) 2022-02-14
EP3455631B1 (en) 2020-06-24
JP2024019551A (ja) 2024-02-09
SG11201809317VA (en) 2018-11-29
RU2018143409A (ru) 2020-06-10
BR112018072993A8 (pt) 2022-11-08
AU2017261685B2 (en) 2023-09-07
PL3455631T3 (pl) 2021-04-06
RU2745730C2 (ru) 2021-03-31
CN115198018A (zh) 2022-10-18
EP3455631A1 (en) 2019-03-20
ES2808004T3 (es) 2021-02-25
KR20190016025A (ko) 2019-02-15
JP7281903B2 (ja) 2023-05-26
MX2018013744A (es) 2019-08-16
CN109690314A (zh) 2019-04-26
RU2018143409A3 (pt) 2020-06-29
JP2019516979A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
BR112018072993A2 (pt) métodos para classificação de um paciente com um câncer sólido
BR112016028958A2 (pt) método in vitro para diagnóstico de osteoporose ou determinação do risco de fraturas osteoporóticas ou monitoramento do tratamento em um indivíduo compreendendo as etapas de coleta de amostra de sangue, de medição do nível de micrornas e de comparação do nível de mirnas com o nível da amostra de referência e composição para tratamento
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
BR112019006004A2 (pt) método e sistema para criação de um intervalo de referência personalizado, e, método para analisar associações clínicas.
MX2019003474A (es) Metodos mejorados para evaluar el estado de la proteina acidica fibrilar glial (gfap) en muestras de pacientes.
MX2019010150A (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5.
BR112019003785A2 (pt) tabaco resistente a vírus e método de melhoramento para o mesmo
BR112018072580A2 (pt) método para operação de um aparelho, produto de programa de computador, e aparelho para determinar pelo menos uma dentre a posição e uma orientação de um dispositivo
WO2016196298A8 (en) Therapeutic and diagnostic methods for cancer
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
UY37594A (es) Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
BR112022004573A2 (pt) Método para identificar respondedores para degradadores de smarca2/4
BR112016004963A2 (pt) biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença
WO2015132670A3 (en) Methods and compositions for detection of targets for autoimmune disease
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
BR112021022879A2 (pt) Sistemas e métodos para avaliação de fração tumoral
BR112018001579A2 (pt) método de detecção de objeto e dispositivo de detecção de objeto
BR122020014835A8 (pt) Método de inspeção de objetos
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
BR112017019285A2 (pt) método e aparelho para produzir informações indicativas de falhas cardíacas
BR112017012287A2 (pt) uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr
MY192377A (en) Method for producing contact lenses with a lubricious surface
WO2020012467A3 (en) Person-specific assessment of probiotics responsiveness
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; SORBONNE UNIVERSITE (FR) ; UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; SORBONNE UNIVERSITE (FR) ; UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS CITE (FR)